ArticleDeveloping a potent therapy for Alzheimer’s disease will be one of the biggest healthcare challenges over the next few decades. Staff Author: Ryan BusheyTopics: Life Sciences https://www.dddmag.com/article/2017/07/new-gene-discoveries-could-redefine-alzheimers-treatment
Almost all Alzheimer’s drugs have failed. But pharma continues to invest millions in hopes of finding a hit, motivated by market opportunity and armed with lessons learned. http://www.biopharmadive.com/news/alzheimers-disease-trends-drug-development-amyloid-biomarkers/447068/
US biotech points to new analysis of phase III results for tramiprosate http://www.pmlive.com/pharma_news/alzheon_says_data_backs_potential_of_alzheimers_candidate_1196981
Merck has signed a worldwide license agreement with Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical antibody candidate targeting the protein tau. http://drugdiscovery.pharmaceutical-business-review.com/news/merck-tejin-sign-license-agreement-for-tau-targeting-antibody-260517-5825579
Leading Alzheimer’s disease researchers and a prominent patient advocate today published an analysis, “Single Endpoint for New Drug Approvals for Alzheimer’s Disease," urging the Food and Drug Administration (FDA) to clarify and modernize its current approach for approving new treatments for Alzheimer’s disease. http://www.worldpharmanews.com/development/3931-alzheimer-s-experts-call-for-changes-in-fda-drug-approval-standards
The FDA has announced its decision to grant a de novo application submitted by 23andMe for the company’s direct-to-consumer (DTC) Personal Genome Service Genetic Health Risk (“GHR") tests. The GHR test panel currently includes genetic variants…By: DLA Piper http://www.jdsupra.com/legalnews/fda-authorizes-first-direct-to-consumer-40610/
Genentech, Roche’s biotech group, has announced its plans to conduct a second Phase 3 study for crenezumab, its anti-Abeta antibody for the treatment of early Alzheimer’s disease.
The trial is designed to further elucidate earlier traces data on the drug’s efficacy in treating Alzheimer’s; crenezumab failed to meet its primary endpoint of slowing cognitive degeneration in mild-to-moderate forms of the disease in two 2014 Phase 2 studies, but did show promise as a treatment in the earliest stages.
read more http://www.pharmafile.com/news/513609/genentech-plans-second-phase-3-alzheimers-trial-following-endpoint-failures